Other
Clopidogrel
0
Pipeline Programs↗
5
Active Trials↗
19
Companies Involved↗
Clopidogrel is an early-stage landscape with 0 programs across 19 companies. The most active players are Sanofi, AstraZeneca, Boehringer Ingelheim.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
140
clinical trials
Completed106 · 76%
Unknown status19 · 14%
Recruiting5 · 4%
Withdrawn5 · 4%
Terminated4 · 3%
Temporarily not available1 · 1%
Clinical Trials
Trial Activity
140 trials
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04937699·2,690 enrolled
Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"
Completed·—·Phase 4·NCT02206815·296 enrolled
75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
Completed·—·Phase 4·NCT00140465·60 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)